Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai, a US subsidiary of Eisai Co, has established Eisai Limited in Canada. As a wholly-owned subsidiary of Eisai, it will be based in Mississauga, Ontario, a biopharmaceutical cluster and medical community in North America.
Subscribe to our email newsletter
Eisai Limited is working with Health Canada on the approval of select products from the Eisai portfolio to be introduced in the Canadian market.
Eisai said that in future, additional medicines from its portfolio of currently marketed products may be introduced to the Canadian market as well as future products from its pipeline. The company’s areas of commercial focus is expected to include neurology, gastrointestinal disorders and oncology/critical care.
Hajime Shimizu, chairman and CEO of Eisai, said: “Eisai’s entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region.
“Most importantly, this new subsidiary will enable Eisai to introduce many of its products to people living in Canada who currently do not have access to these treatments, further supporting Eisai’s human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide.”